A Phase 1, Randomized, Double-blind, Multi-center, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Healthy Japanese Infants 5 Months of Age at First Trial Vaccine Administration
Latest Information Update: 18 Mar 2025
At a glance
- Drugs HIL 214 (Primary)
- Indications Gastroenteritis
- Focus Adverse reactions
- Sponsors HilleVax
Most Recent Events
- 14 Mar 2025 Status changed from active, no longer recruiting to completed.
- 20 Mar 2024 According to a HilleVax media release, as of October 2023 enrollment of subjects completed.
- 14 Nov 2023 Status changed from recruiting to active, no longer recruiting.